• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Rhythm Pharmaceuticals Inc (NQ: RYTM )

    44.94 +1.18 (+2.70%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 9, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 401,216
    Open 43.66
    Bid (Size) 42.37 (1)
    Ask (Size) 47.88 (1)
    Prev. Close 43.76
    Today's Range 43.66 - 45.46
    52wk Range 15.61 - 52.57
    Shares Outstanding 60,972,909
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -0.42%
    -0.42%
    1 Month
    +9.58%
    +9.58%
    3 Month
    +7.51%
    +7.51%
    6 Month
    +0.99%
    +0.99%
    1 Year
    +176.38%
    +176.38%

    More News

    Read More
    Rhythm Pharmaceuticals Announces New Employment Inducement Grants
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Analyst Expectations For Rhythm Pharmaceuticals's Future
    Via Benzinga
    5 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know
    Via Benzinga
    Analyst Expectations For Rhythm Pharmaceuticals's Future
    Via Benzinga
    Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals Announces New Employment Inducement Grants
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    The 3 Best Nasdaq Stocks to Buy in May 2024
    Via InvestorPlace
    RYTM Stock Earnings: Rhythm Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Jim Cramer Is 'Willing To Let This Pharma Stock Catch Fire,' Advises Not To Sell McKesson
    Via Benzinga
    Rhythm Pharmaceuticals Announces New Employment Inducement Grants
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    7 Stocks That Will Drive the Weight Loss Drugs Market
    Via MarketBeat
    Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals Announces New Employment Inducement Grants
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.